2016
DOI: 10.1016/j.ijcard.2016.07.241
|View full text |Cite
|
Sign up to set email alerts
|

Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
6
1

Year Published

2018
2018
2021
2021

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 10 publications
(9 citation statements)
references
References 39 publications
2
6
1
Order By: Relevance
“…In this study, we found no associations between high HbA1c and galectin-3, indicating that they are two independent biomarkers associated with depression. Our results differ from previous research as we did not find any associations between high galectin-3 and age, hypertension, hypercholesterolemia, triglycerides, s-LDL, BMI, s-creatinine or smoking ( 19 , 21 , 22 , 23 ). In none of these previous studies had the results been controlled for depression, the results might have been different if they had.…”
Section: Discussioncontrasting
confidence: 99%
See 1 more Smart Citation
“…In this study, we found no associations between high HbA1c and galectin-3, indicating that they are two independent biomarkers associated with depression. Our results differ from previous research as we did not find any associations between high galectin-3 and age, hypertension, hypercholesterolemia, triglycerides, s-LDL, BMI, s-creatinine or smoking ( 19 , 21 , 22 , 23 ). In none of these previous studies had the results been controlled for depression, the results might have been different if they had.…”
Section: Discussioncontrasting
confidence: 99%
“…In Alzheimer’s disease, increased levels of serum galectin-3 have been demonstrated ( 15 ). Significant associations have previously been found between galectin-3 and age, sex, type 2 diabetes mellitus, hypertension, hypercholesterolemia, triglycerides, LDL, BMI, renal dysfunction and smoking ( 19 , 21 , 22 , 23 ). Metformin in type 2 diabetes mellitus has, however, been linked to lower galectin-3 levels ( 22 ).…”
Section: Introductionmentioning
confidence: 95%
“…Clinical correlates of change in Gal-3 in our study are in keeping with two prior studies examining temporal changes in Gal-3 levels: Among patients with existing HF, Anand, et al found that lower baseline Gal-3 levels, lower eGFR, interim decrease in eGFR, female sex, and higher BMI were associated with greater increases in Gal-3 levels at 4 months (19). Similarly, in the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) study, investigators showed that in general population, systolic blood pressure >170 mmHg and urinary albumin excretion >30 mg/24 h were independent predictors of dynamic increase in Gal-3 levels across a time span of 9 years (17). We validate hypertension as a predictor, but extend these findings by showing that diabetes and obesity are also associated with a rise in Gal-3 over the span of about a decade.…”
Section: Discussionmentioning
confidence: 99%
“…Despite relatively low biological variation (14), plasma Gal-3 levels do change over time (15) and Gal-3 trajectory might be independent of baseline levels (16). Systolic blood pressure and urinary excretion of albumin were shown to predict temporal changes in Gal-3 levels (17). Prior studies have shown that serial measurements of Gal-3 provides incremental prognostic information in patients with existing HF (8,18,19).…”
Section: Introductionmentioning
confidence: 99%
“…It is interesting to note that, although NT-proBNP and troponin were shown to be predictive for incident HF in the general population, the predictive value of sST2, Gal3, and other non-cardiac-specific markers is limited and some sex-specific differences have been observed [90,121]. Interestingly, longitudinal changes in Gal-3 concentrations appear to have stronger predictive value for future cardiovascular diseases as compared to single measurements [122,123]. Thus, sequential biomarker analysis may provide better resolutions in subclinical populations.…”
Section: Non-cardiac-specific Plasma Biomarkers In Subclinical Heart Diseasementioning
confidence: 99%